This is the authors' abstract. We don't add key points for this paper.
Germline heterozygous BAP1 pathogenic/likely pathogenic (P/LP) variants are associated with the BAP1 -tumor predisposition syndrome ( BAP1 -TPDS). This study evaluated evidence for an association between ovarian cancers and BAP1 -TPDS. We evaluated ovarian cancer incidence in two independent cohorts of female subjects with germline BAP1 P/LP variants. Additionally, we investigated whether the high incidence of spontaneous ovarian sex cord-stromal tumors (OSCSTs) in heterozygous Bap1 -mutant FVB/N mice was strain-specific by examining their occurrence in several other Bap1 -mutant mouse models with different genetic backgrounds. In the combined human cohort of 176 females with BAP1 P/LP variants, 7 (4%) had ovarian cancer, including 3 with OSCST. Another OSCST occurred in a patient with a germline BAP1 variant with conflicting pathogenesis, for which functional studies supported pathogenicity. OSCSTs were observed in all mouse strains with germline heterozygous Bap1 mutations (incidence: 32%–73%). Biallelic inactivation of BAP1 was observed in 3/3 human and 10/10 murine OSCSTs. OSCSTs from Bap1 -mutant mice showed marked decreases in Bmpr1b , Erb , and Foxl2 expression, suggesting disruption of pathways involved in ovarian differentiation and homeostasis. In conclusion, ovarian cancers, particularly OSCSTs, represent a rarer phenotype of the BAP1 -TPDS. Downregulation of Bmpr1b , Erb , and Foxl2 may reflect alterations in pathways amenable to therapeutic targeting in OSCSTs.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: